Anti-tumor activity of the novel angiogenesis inhibitor anginex

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Angiogenesis is crucial for tumor growth and metastasis.
• Targeting angiogenesis offers a therapeutic strategy for cancer treatment.
• Anginex is a novel peptide with demonstrated anti-angiogenic properties.

Purpose of the Study:

• To evaluate the in vivo efficacy of Anginex as an anti-tumor agent.
• To assess the anti-angiogenic mechanism of Anginex in preclinical cancer models.
• To determine the safety and optimal administration of Anginex.

Main Methods:

• In vivo efficacy studies using mouse xenograft models (MA148 ovarian carcinoma).
• Systemic administration via osmotic mini-pumps and daily injections.
• Anginex conjugation to human serum albumin to improve bioavailability.
• Immunohistochemical analysis of microvessel density and in vitro angiogenesis assays.
• Comprehensive toxicity assessment including behavioral, weight, blood, and morphological analyses.

Main Results:

• Anginex significantly inhibited tumor growth in a dose-dependent manner, achieving up to 80% reduction.
• Optimal efficacy was observed with continuous administration (10 mg/kg/day) via mini-pumps.
• Conjugation to human serum albumin enhanced Anginex's anti-tumor effect.
• Anginex suppressed tumor angiogenesis, confirmed by reduced microvessel density and impaired in vitro tube formation.
• No signs of toxicity were detected in treated animals.

Conclusions:

• Anginex is a potent anti-angiogenic agent with significant in vivo anti-tumor activity.
• Continuous administration and improved bioavailability enhance Anginex's therapeutic potential.
• Anginex represents a promising, non-toxic therapeutic candidate for cancer treatment by targeting tumor angiogenesis.